期刊文献+

人结肠癌变组织中血管内皮生长因子微血管密度CXCR-4的表达及其意义 被引量:2

Expression of MVD,VEGF and CXCR-4 in human colon cancer and their significance
下载PDF
导出
摘要 目的探讨血管内皮生长因子(VEGF)、微血管密度(MVD)和趋化因子受体CXCR-4基因在结肠恶性病变中的表达及意义。方法收集经手术切除且病理证实的结肠癌病例68例,所有患者术前均未经放疗或化疗,记录各患者肿瘤部位,组织学类型,病理分期等临床资料,采用免疫组织化学法检测标本中VEGF、CX-CR-4和MVD的表达。结果 VEGF,CXCR-4和MVD表达与患者的分化程度、组织学类型无关(P>0.05)。VEGF,CXCR-4和MVD表达与结肠癌临床分期和淋巴结转移差异有统计学意义(P<0.05)。结论三者联合检测可能有助于结肠癌的病理学分期诊断。 Objective To investigate the expression of vascular endothelial growth factor (VEGF), mi- crovessel density (MVD) and the CXCR-4 chemokine receptor gene in malignant lesions of the colon cancer and their significance. Methods 68 cases of colon cancer cases confirmed by surgery and pathology are enrolled. All patients with preoperative radiotherapy or chemotherapy. Clinical data for tumor location, histological type, path- ological stage of patients were recorded. Immunohistochemical assay was used to analyze the expression of VEGF, CXCR-4 and MVD. Results VEGF, CXCR-4 and MVD in patients are not correlated with the degree of differenti ation and histological type (P〉0.05). VEGF, MVD and CXCR-4 in patients with colon cancer are significantly correlated with clinical stage and lymph node metastasis (P〈0.05). Conclusion Joint detection of VEGF, MVD and CXCR-4 may contribute to pathological staging in colon cancer.
出处 《山西医药杂志(上半月)》 CAS 2012年第6期542-543,共2页 Shanxi Medical Journal
基金 湖南省科学技术厅基金(B2011-065)
关键词 结肠肿瘤 免疫组织化学 血管内皮生长因子类 CXCR4 微血管密度 Colon neoplasms Immunohistoehemistry Vascular endothelial growth aetors CXCR4 Microvascula density
  • 相关文献

参考文献4

二级参考文献26

  • 1贾葆青.VEGF与MMP-2在结肠癌组织的表达及相互关系的研究[J].内蒙古医学院学报,2007,29(S1):489-491. 被引量:4
  • 2牟江洪,阎晓初,王东,吴小华,李增鹏,向德兵.大肠癌组织中VEGF-D的表达及其与淋巴结转移和预后的关系[J].肿瘤防治杂志,2005,12(3):202-206. 被引量:4
  • 3朱新峰,林坚.血管内皮生长因子与肿瘤关系研究进展[J].广西医科大学学报,2006,23(2):333-335. 被引量:23
  • 4Ferrara N,Kerbel R S.Angiogenesis as a therapeutic target[J].Nature,2005,438 (7070):967-974.
  • 5Dejardin E,Deregowski V,Chapelier M,et al.Regulation of NF-kappa B activity by I kappa B-related proteins in adenocarcinoma cells[J].Oncogene,1999,18(16):2567-2577.
  • 6Cooney M M,Van H W,Bhakta S,et al.Drug Insight:vascular disrupting agents and angiagenesis-novei approaches for drug delivery[J].Nat Clin Pract Oncol,2006,3(12):682-692.
  • 7Ferrara N,Gerber H P,Leconter J,et al.The biology of VEGF and its receptors[J].Nat Med,2003,9(6):669-676.
  • 8Nagy J A,Vasile E,Feng D,et al.Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis[J].J Exp Med,2002,196 (11):1497-1506.
  • 9Cursiefen C,Cben L,Borges L P,et al.VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularizatian via macrophage recruitment[J].J Clin Invest,2004,113(7):1040-1050.
  • 10Kieser A,Weieh H A,Brandner G,et al.Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression[J].Oncogenc,1994,9(3):963-969.

共引文献13

同被引文献5

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部